Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by ualcin1on May 20, 2020 12:25pm
112 Views
Post# 31051859

RE:Equity raise or LoC

RE:Equity raise or LoCIn my opinion, until the FDA approves the BLA, I cannot conceive of a rational and informed investor wanting to acquire an interest in Liminal. This company is earning meager revenues compared to extremely large expenses, with no prospects for growth in the absence of FDA approval. And if one looks at the history of the BLA file, an investor would realize the hesitations and disappointed promises that have been part of this file from the Laurin era to the present. In my opinion, I cannot see a share issue that is likely to be successful, even at a ridiculously low price. So, in reality, Liminal has no choice but to resort to its LOC until the FDA approves the BLA. Otherwise, the only other option left is the one we experienced last year, which was a highly dilutive share issue for the benefit of shareholders we all know very well.
<< Previous
Bullboard Posts
Next >>